Panelists discuss how the recent FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC) expands treatment options, offering improved tolerability with lower fatigue ...
IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...
An expert discusses how KEYNOTE-905 establishes a new evidence-based systemic therapy option that transforms the management and prognosis of patients with muscle-invasive bladder cancer. The ...
Gedatolisib and darolutamide combination targets PAM and AR pathways, potentially inducing a synergistic anti-tumor effect in mCRPC patients. Phase 1 trial with 38 patients showed promising safety, ...
At the 2025 LUGPA Annual Meeting, Jonathan Henderson, MD, delivered a talk titled, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.” During the meeting, Henderson sat down with ...
Theranostic therapies are advancing rapidly, with nearly 90 products in early-stage trials, expanding access to more patients and reshaping clinical practice in urologic oncology. Radioligand therapy, ...
Most NMIBC patients rely on healthcare providers for treatment decisions, but desire more comprehensive discussions about options. Patients prefer treatments beyond chemotherapy, with 81% interested ...
The FDA plans to remove the black box warning on HRT for menopause, except for endometrial cancer warnings on systemic estrogen-alone products. Expert recommendations and literature reviews suggest ...
The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...
The BioProtect Balloon Spacer significantly preserves bowel, urinary, and sexual quality of life in prostate cancer patients undergoing radiation therapy over four years. The study showed ...
The subcutaneous formulation of pembrolizumab is approved for all adult indications in Europe, offering faster administration than the intravenous version. Phase 3 trial results showed noninferior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback